Patents Assigned to GEISTLICH PHARMA AG
-
Publication number: 20200324020Abstract: A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.Type: ApplicationFiled: April 10, 2020Publication date: October 15, 2020Applicants: Geistlich Pharma AG, University of Southern CaliforniaInventors: Charles ZELEN, David ARMSTRONG, Paul GLAT, Jarrod KAUFMAN, Marco MEHR, Lothar SCHLOESSER, Mark SPILKER
-
Patent number: 10736902Abstract: A method of treating a patient suffering from TNBC by a multidisciplinary method involving treating the patient with a plurality of the following treatments: i) one or more checkpoint inhibitors; ii) hyperthermia treatment; iii) low dose chemotherapy; iv) Interleukin-2 (IL-2); and v) a compound selected from the group consisting of taurolidine, taurultam, oxathiazin-like compounds, and combinations thereof.Type: GrantFiled: March 17, 2017Date of Patent: August 11, 2020Assignee: GEISTLICH PHARMA AGInventors: H. Paul Redmond, Rolf W. Pfirrmann
-
Patent number: 10695461Abstract: A dried implant composition for preparing an injectable aqueous implant formulation that is extrudable through a tapering system and a gauge 18 cannula, including a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 ?m and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve; an injectable aqueous implant formulation for use in a method of oral tissue regeneration, wherein the injectable aqueous implant formulation is obtainable by hydration and homogeneous mixing; a process for preparing the injectable aqueous implant formulation; and a kit for preparing the injectable aqueous implant formulation for use in oral tissue regeneration.Type: GrantFiled: December 14, 2018Date of Patent: June 30, 2020Assignee: Geistlich Pharma AGInventors: Daniel Suppiger, Paul Buxton, Nino Kurz
-
Patent number: 10646615Abstract: A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and a closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a homogeneous coarse external surface comprising flat crystal platelets, which shows an enhanced osteogenic response, a method of promoting bone formation, bone regeneration and/or bone repair by implanting the biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material, and a process of preparation thereof.Type: GrantFiled: September 25, 2019Date of Patent: May 12, 2020Assignee: Geistlich Pharma AGInventors: Claudio Zihlmann, Michael Bufler
-
Patent number: 10646619Abstract: A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface, which material shows an increased capacity to induce bone formation, and a process of preparation thereof.Type: GrantFiled: December 14, 2018Date of Patent: May 12, 2020Assignee: GEISTLICH PHARMA AGInventors: Claudio Zihlmann, Michael Bufler
-
Patent number: 10544114Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes for efficient and safe manufacture of compounds useful for making oxathiazin-like compounds useful for treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed.Type: GrantFiled: April 6, 2017Date of Patent: January 28, 2020Assignee: GEISTLICH PHARMA AGInventor: Rolf W. Pfirrmann
-
Publication number: 20200016293Abstract: A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and a closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a homogeneous coarse external surface comprising flat crystal platelets, which shows an enhanced osteogenic response, a method of promoting bone formation, bone regeneration and/or bone repair by implanting the biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material, and a process of preparation thereof.Type: ApplicationFiled: September 25, 2019Publication date: January 16, 2020Applicant: GEISTLICH PHARMA AGInventors: Claudio ZIHLMANN, Michael BUFLER
-
Publication number: 20190389819Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.Type: ApplicationFiled: August 12, 2019Publication date: December 26, 2019Applicant: GEISTLICH PHARMA AGInventor: Rolf W. PFIRRMANN
-
Patent number: 10392355Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.Type: GrantFiled: December 17, 2015Date of Patent: August 27, 2019Assignee: GEISTLICH PHARMA AGInventor: Rolf W. Pfirrmann
-
Publication number: 20190209735Abstract: A dried implant composition for preparing an injectable aqueous implant formulation that is extrudable through a tapering system and a gauge 18 cannula, including a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 ?m and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve; an injectable aqueous implant formulation for use in a method of oral tissue regeneration, wherein the injectable aqueous implant formulation is obtainable by hydration and homogeneous mixing; a process for preparing the injectable aqueous implant formulation; and a kit for preparing the injectable aqueous implant formulation for use in oral tissue regeneration.Type: ApplicationFiled: December 14, 2018Publication date: July 11, 2019Applicant: GEISTLICH PHARMA AGInventors: Daniel SUPPIGER, Paul BUXTON, Nino KURZ
-
Publication number: 20190209737Abstract: A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface, which material shows an increased capacity to induce bone formation, and a process of preparation thereof.Type: ApplicationFiled: December 14, 2018Publication date: July 11, 2019Applicant: GEISTLICH PHARMA AGInventors: Claudio Zihlmann, Michael Bufler
-
Publication number: 20190184059Abstract: A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and a closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a homogeneous coarse external surface comprising flat crystal platelets, which shows an enhanced osteogenic response, a method of promoting bone formation, bone regeneration and/or bone repair by implanting the biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material, and a process of preparation thereof.Type: ApplicationFiled: December 14, 2018Publication date: June 20, 2019Applicant: GEISTLICH PHARMA AGInventors: Claudio ZIHLMANN, Michael BUFLER
-
Patent number: 10300171Abstract: A resorbable crosslinked form stable membrane containing a composite layer of collagen material and inorganic ceramic particles containing 1.5 to 3.5 weight parts of inorganic ceramic for 1 weight part of collagen material, sandwiched between two layers of elastic pretensed collagen material, wherein the elastic pretensed collagen material is collagen material that has been stretched such as to be in the linear/elastic region of the stress-strain curve, the collagen material comprising 50-100% (w/w) collagen and 0-50% (w/w) elastin.Type: GrantFiled: May 10, 2018Date of Patent: May 28, 2019Assignee: Geistlich Pharma AGInventors: Niklaus Stiefel, Sergej Stenzel, Raphael Kaufmann
-
Publication number: 20190091233Abstract: A method of treating a patient suffering from TNBC by a multidisciplinary method involving treating the patient with a plurality of the following treatments: i) one or more checkpoint inhibitors; ii) hyperthermia treatment; iii) low dose chemotherapy; iv) Interleukin-2 (IL-2); and v) a compound selected from the group consisting of taurolidine, taurultam, oxathiazin-like compounds, and combinations thereof.Type: ApplicationFiled: March 17, 2017Publication date: March 28, 2019Applicant: GEISTLICH PHARMA AGInventors: H. Paul REDMOND, Rolf W. PFIRRMANN
-
Publication number: 20190084950Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes for efficient and safe manufacture of compounds useful for making oxathiazin-like compounds useful for treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed.Type: ApplicationFiled: April 6, 2017Publication date: March 21, 2019Applicant: GEISTLICH PHARMA AGInventor: Rolf W. PFIRRMANN
-
Publication number: 20180370932Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.Type: ApplicationFiled: December 17, 2015Publication date: December 27, 2018Applicant: GEISTLICH PHARMA AGInventor: Rolf W. PFIRRMANN
-
Publication number: 20180344902Abstract: The invention relates to resorbable crosslinked form stable membrane which comprises a composite layer of collagen material and inorganic ceramic particles containing 1.5 to 3.5 weight parts of inorganic ceramic for 1 weight part of collagen material, sandwiched between two layers of elastic pretensed collagen material (collagen material that has been stretched such as to be in the linear/elastic region of the stress-strain curve), the collagen material comprising 50-100% (w/w) collagen and 0-50% (w/w) elastin, and has shape and dimensions suitable for use in human tissue regeneration outside the oral cavity in rhinoplasty, postlateral spinal fusion or orbital reconstruction.Type: ApplicationFiled: June 1, 2018Publication date: December 6, 2018Applicant: GEISTLICH PHARMA AGInventors: Niklaus STIEFEL, Sergej STENZEL, Raphael KAUFMANN
-
Publication number: 20180256785Abstract: A resorbable crosslinked form stable membrane containing a composite layer of collagen material and inorganic ceramic particles containing 1.5 to 3.5 weight parts of inorganic ceramic for 1 weight part of collagen material, sandwiched between two layers of elastic pretensed collagen material, wherein the elastic pretensed collagen material is collagen material that has been stretched such as to be in the linear/elastic region of the stress-strain curve, the collagen material comprising 50-100% (w/w) collagen and 0-50% (w/w) elastin.Type: ApplicationFiled: May 10, 2018Publication date: September 13, 2018Applicant: GEISTLICH PHARMA AGInventors: Niklaus STIEFEL, Sergej STENZEL, Raphael KAUFMANN
-
Patent number: 10029028Abstract: The invention relates to: —a biomimetic collagen-hydroxyapatite composite material comprising an at least partially fibrous collagen scaffold including mature native collagen fibers possessing triple helicity as shown by Circular Dichroism Spectroscopy, wherein those mature native collagen fibers are at least partially covered with epitactically grown crystals of nanocrystalline hydroxyapatite, whereby the epitactically grown nanocrystals have the same morphology as human bone mineral and the same size as human bone mineral, i.e.Type: GrantFiled: July 18, 2014Date of Patent: July 24, 2018Assignee: Geistlich Pharma AGInventor: Michael Bufler
-
Patent number: 9844555Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.Type: GrantFiled: March 29, 2017Date of Patent: December 19, 2017Assignee: Geistlich Pharma AGInventor: Rolf W. Pfirrmann